Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 64Magnetic Resonance Spectroscopy 44Carboplatin 34Cyclophosphamide 31Gemcitabine 29Biopsy 28Cisplatin 27Radiotherapy 26pembrolizumab 25Bevacizumab 25Paclitaxel 23Standard of Care 22Oxaliplatin 22Drug Therapy 22venetoclax 21Nivolumab 21Capecitabine 21fludarabine 20Injections 20Interviews as Topic 18Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16toripalimab 15tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13Pemetrexed 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Emapalumab × 90 days × Clear all
NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡